www.fdanews.com/articles/206497-pfizer-valneva-tout-positive-phase-2-data-for-lyme-disease-vaccine
Pfizer, Valneva Tout Positive Phase 2 Data for Lyme Disease Vaccine
February 8, 2022
Pfizer and Valneva reported positive findings from a phase 2 clinical trial showing that their Lyme disease vaccine candidate, VLA15, induced an immune response.
Antibody levels were higher in participants who received a three-dose primary series vs. a two-dose series, the companies said, so a three-dose regimen is planned in a phase 3 study expected to begin in the third quarter of 2022.
Pfizer entered into a $308 million co-development and licensing agreement in April 2020 with the French biotech company under which Valneva will receive royalties on future sales.